New obesity drug GZR18 under microscope: how does it interact with common meds?
NCT ID NCT07128888
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 36 times
Summary
This early-stage study tests GZR18, an injectable drug for obesity or overweight, in 60 Chinese adults. Researchers want to see how it affects stomach emptying and whether it changes how the body processes digoxin (heart medication), rosuvastatin (cholesterol drug), and warfarin (blood thinner). Participants receive GZR18 for 16 weeks, then take the other drugs for 6 weeks while being monitored. The goal is to understand safety and dosing, not to treat obesity directly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Study site 01
RECRUITINGBeijing, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GZR18 injection
What this could lead to
If successful, this study could help determine safe use of GZR18 with common medications like heart drugs, statins, and blood thinners in people with obesity.
What could go wrong
This is an early Phase 1 trial with only 60 participants, so results may not apply to everyone. The main goal is safety and drug interaction, not weight loss or disease treatment.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.